Home > Healthcare & Medical Devices > Allergy Therapeutics Market

Allergy Therapeutics Market - By Treatment (Anti-allergy drug [Antihistamine, Corticosteroid, Decongestant], Immunotherapy [SCIT, SLIT]), Type (Rhinitis, Asthma, Skin, Food, Eye), Route of Administration, Distribution Channel, Global Forecast, 2023 – 2032

  • Report ID: GMI6560
  • Published Date: Aug 2023
  • Report Format: PDF

Allergy Therapeutics Industry Analysis

Allergy Therapeutics Market size accounted for USD 21.7 billion in 2022 and is expected to reach USD 41.2 billion by 2032, increasing at a CAGR of 6.6% from 2023 to 2032. The rising incidence of allergic disorders is one of the main drivers of the market.

Allergy Therapeutics Market

To get more details on this report: Request Free Sample PDF

Allergies such as allergic rhinitis, asthma, food allergies, and atopic dermatitis have become more frequent in recent years. According to the CDC's National Centre for Health Statistics, over one-third of U.S. adults and more than one-fourth of U.S. children affected by a seasonal allergy, eczema, or food allergy in 2021. This surge in incidence is linked to causes such as increasing environmental exposures, genetics, growing urbanisation, and lifestyle changes.

Moreover, continuous advances in medical research have resulted in greater understanding of allergic disorders, their underlying processes, and prospective therapy targets. This understanding has aided in the creation of more effective and tailored allergy therapies. In addition, allergic conditions can have a substantial influence on a person's quality of life. The need for effective allergy relief drives the demand for new and improved treatment alternatives that provide greater symptom management and overall well-being.

COVID-19 Impact

The COVID-19 pandemic had a significant impact on the allergy therapeutics market. The downtime of global supply chains, including pharmaceutical manufacture and delivery, had hampered the availability of some allergy drugs. This might have resulted in shortages or delays in obtaining specialised therapies. Additionally, many non-urgent healthcare appointments were postponed or cancelled during the early stages of the pandemic, resulting in delayed identification and treatment for allergic diseases. Patients with allergies may have avoided seeking medical attention owing to concerns about being exposed to the virus in hospital settings.

However, the pandemic spurred the usage of telemedicine and virtual consultations. While this allowed healthcare personnel to communicate with patients remotely, it has hindered the capacity to do some tests or examinations necessary for correct allergy diagnosis.


Overall, COVID-19 has a diversified influence on the market. While there were delays and interruptions, there were also potential for enhanced awareness and improved approaches to patient care through telemedicine and other digital alternatives. As the situation evolved, it was critical to conduct continual research and adaptation to ensure that persons with allergies receive proper care and treatment.


Allergy Therapeutics Market Trends

The market is experiencing several notable trends that are shaping its growth and development. Some key trends in the market includes increasing personalized medicine and precision therapies, rising adoption of biologic therapies, such as monoclonal antibodies, are gaining traction in the treatment of severe allergic conditions like asthma and chronic urticaria, innovative methods of allergen immunotherapy, including sublingual tablets, patches, and intratympanic immunotherapy, and increasing integration of digital technologies, including mobile apps, wearables, and telemedicine platforms, is enhancing patient engagement, remote monitoring, and access to allergy specialists.

Moreover, food allergy awareness is increasing, prompting research into novel treatments such as oral immunotherapy and other desensitization approaches. The approval of the first peanut allergy treatment marked a significant milestone in this area.

Allergy Therapeutics Treatment type Segmentation

 Allergy Therapeutics Market Size, By Treatment Type,

To get more details on this report: Request Free Sample PDF

Based on treatment type, the allergy therapeutics market is segmented as anti-allergy drugs and immunotherapy. The anti-allergy drugs are further segmented into antihistamines, corticosteroids, decongestants, and other drugs. The immunotherapy is further segmented into sub-cutaneous Immunotherapy (SCIT), and sub-lingual Immunotherapy (SLIT). The anti-allergy drugs segment accounted for the largest share of 84% in 2022. The rising prevalence of allergies in children has created a significant demand for paediatric-friendly anti-allergy drugs. Medications designed for children and infants address the unique needs of young patients.

Based on type of anti-allergy drugs, the corticosteroids segment accounted for the highest share in 2022. Corticosteroids come in various forms, including oral tablets, inhalers, nasal sprays, creams, ointments, and injections. This versatility allows for targeted delivery to specific affected areas, making them suitable for treating a wide range of allergic conditions, from asthma to eczema.

Allergy Therapeutics Type Segmentation

Allergy Therapeutics Market Share, By Type

To get more details on this report: Request Free Sample PDF

Based on type, the allergy therapeutics market is segmented as eye allergy, asthma, skin allergy, food allergies, rhinitis, and other allergy types. The rhinitis segment held dominant market share of around 19.5% in 2022 and is expected to grow at a significant pace of 6.4% during the forecast period. Allergic rhinitis is one of the most common chronic diseases in the globe. It affects a significant percentage of the worldwide population, encompassing a wide range of age groups and demographics. Owing to this high incidence, there is a significant desire for effective therapies that can relieve symptoms and enhance quality of life. Furthermore, seasonal allergens (pollen) or perennial allergens (dust mites, animal dander) can cause allergic rhinitis. The year-round presence of diverse allergy triggers raises the demand for therapeutic options.


Allergy Therapeutics Route of Administration Segmentation

Based on route of administration, the allergy therapeutics market is segmented oral, inhalers, intranasal, and other routes of administration. The oral segment was anticipated to be worth USD 11.2 billion in 2022 and is expected to grow at 6.6% CAGR during the forecast period. Oral medications offer a convenient and user-friendly method of treatment. Patients can take their medication anywhere and at any time without the need for specialized equipment or administration techniques. This ease of use contributes to better treatment adherence. Furthermore, oral medications are often preferred for pediatric and geriatric patients who may have difficulty using other administration methods, such as nasal sprays or inhalers. Oral medications can be administered to patients of various ages and abilities. This will increase the demand for oral medication in the market.

Allergy Therapeutics Distribution Channel Segmentation

Based on distribution channel, the allergy therapeutics market is segmented as hospital pharmacies, retail pharmacies, and other distribution channels. The hospital pharmacies segment held a dominant market share of 54.6% in 2022 and is expected to grow at a CAGR of 6.5% from 2023 to 2032. Hospital pharmacies are a primary source of medications for patients receiving care within hospital settings, including emergency departments, intensive care units, and surgical units. Allergic reactions can occur suddenly and require immediate treatment, making hospital pharmacies essential for providing rapid access to allergy medications, hence contribute to the effective management of allergy therapeutics and the overall well-being of patients.


Allergy Therapeutics Regional Analysis

North America Allergy Therapeutics Market Size,

North America allergy therapeutics market accounted for significant revenue in 2022 and is expected to reach USD 17.2 billion in 2032 with a CAGR of 6.7% from 2023-2032. North America has a relatively high prevalence of allergic conditions, including allergic rhinitis, asthma, atopic dermatitis, and food allergies. Environmental factors, genetic predisposition, and lifestyle changes contribute to the widespread occurrence of allergies in the region.

Moreover, awareness about allergic conditions and their impact on health has grown significantly in North America. Greater awareness prompts individuals to seek medical attention, leading to improved diagnosis rates and the demand for effective allergy therapeutics. Additionally, North America boasts advanced healthcare systems with well-established medical facilities, hospitals, clinics, and specialty practices. This infrastructure supports the diagnosis, treatment, and management of allergic conditions, driving the demand for therapeutics, leading to the regional progress.

Allergy Therapeutics Industry Leaders

Some of the major market players operating in the allergy therapeutics market are Allergopharma, Danaher, AbbVie, Inc., Allergy Therapeutics plc, Sanofi SA, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., and Merck & Co., Inc. These players focus on strategic partnerships, new type launch & commercialization for market expansion.

Allergy Therapeutics Industry News:

  • In August 2020, Nestlé and Aimmune Therapeutics, Inc. signed an agreement under which Nestlé Health Science (NHSc) acquired Aimmune. Palforzia by Aimmune is the first and only FDA-approved therapy to help reduce the frequency and severity of peanut allergy reactions, including anaphylaxis, in children aged 4 to 17. This acquisition expands NHSc's food allergy portfolio, providing a greater range of options for children with food allergies.

The allergy therapeutics market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032, for the following segments:

Click here to Buy Section of this Report

By Treatment type, 2018 - 2032 (USD Million)

  • Anti-allergy drugs
    • Antihistamines
    • Corticosteroids
    • Decongestants
    • Other drugs
  • Immunotherapy
    • Sub-cutaneous immunotherapy (SCIT)
    • Sub-lingual immunotherapy (SLIT)

By Type, 2018 - 2032 (USD Million)

  • Eye allergy
  • Asthma
  • Skin allergy
  • Food allergies
  • Rhinitis
  • Other allergy types

By Route of administration, 2018 - 2032 (USD Million)

  • Oral
  • Inhalers
  • Intranasal
  • Other routes of administration

By Distribution Channel, 2018 - 2032 (USD Million)

  • Hospital pharmacies
  • Retail pharmacies
  • Other distribution channels

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • Rest of Asia Pacific 
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • Rest of Middle East & Africa


Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The allergy therapeutics market size was around USD 21.7 billion in 2022 and will reach USD 41.2 billion by 2032.

The rhinitis segment size was around 19.5% in 2022 and will record nearly 6.4% CAGR from 2023 to 2032 as it is one of the most common chronic diseases across the globe, fueling the demand for effective therapies that can relieve symptoms and enhance quality of life.

North America allergy therapeutics market size is expected to reach USD 17.2 billion in 2032 with a CAGR of 6.7% from 2023-2032 as the region has a relatively high prevalence of allergic conditions, including allergic rhinitis, asthma, atopic dermatitis, and food allergies.

Allergopharma, Danaher, AbbVie, Inc., Allergy Therapeutics plc, Sanofi SA, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., and Merck & Co., Inc.

Buy Now

Access to only 1 person; cannot be shared; cannot be printed
Access for 2 to 5 users only within same department of one company
Access to a company wide audience; includes subsidiary companies or other companies within a group of companies

Premium Report Details

  • Base Year: 2022
  • Companies covered: 10
  • Tables & Figures: 374
  • Countries covered: 19
  • Pages: 215
Inquiry Before Buying

Budget constraints? Get in touch with us for special pricing

Request Discount